These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 18406454)
1. Drugs that interact with cardiac electro-mechanics: old and new targets for treatment. Kirchhof P; Fortmüller L; Waldeyer C; Breithardt G; Fabritz L Prog Biophys Mol Biol; 2008; 97(2-3):497-512. PubMed ID: 18406454 [TBL] [Abstract][Full Text] [Related]
2. Cellular basis for triggered ventricular arrhythmias that occur in the setting of compensated hypertrophy and heart failure: considerations for diagnosis and treatment. Antoons G; Oros A; Bito V; Sipido KR; Vos MA J Electrocardiol; 2007; 40(6 Suppl):S8-14. PubMed ID: 17993335 [TBL] [Abstract][Full Text] [Related]
3. Clinical applications of antiarrhythmic drugs. Lavenne F; de Jonghe D Acta Cardiol Suppl; 1980; (25):27-42. PubMed ID: 6155012 [No Abstract] [Full Text] [Related]
4. Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part I: Molecular and ionic fundamentals of antiarrhythmic drug actions. Calò L; Sciarra L; Lamberti F; Loricchio ML; Castro A; Bianconi L; Pandozi C; Gaita F; Santini M Ital Heart J; 2003 Jul; 4(7):430-41. PubMed ID: 14558293 [TBL] [Abstract][Full Text] [Related]
5. Potential application of late sodium current blockade in the treatment of heart failure and atrial fibrillation. Doshi D; Morrow JP Rev Cardiovasc Med; 2009; 10 Suppl 1():S46-52. PubMed ID: 19898288 [TBL] [Abstract][Full Text] [Related]
10. Is there a role for digoxin in atrial fibrillation without heart failure? Master J; Schweitzer P Cardiol J; 2009; 16(5):483-6. PubMed ID: 19753533 [TBL] [Abstract][Full Text] [Related]
11. [Influence of antifibrillatory drugs on electric elementary processes]. Fleckenstein A Verh Dtsch Ges Kreislaufforsch; 1969; 35():77-87. PubMed ID: 4985686 [No Abstract] [Full Text] [Related]
13. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Makkar KM; Sanoski CA; Spinler SA Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795 [TBL] [Abstract][Full Text] [Related]
14. Effects of class I antiarrhythmic drugs on the digitalis-induced triggered activity arrhythmia model: a rationale for the short-term use of class I drugs against triggered arrhythmias. Takahara A; Sugiyama A; Hashimoto K Heart Vessels; 2004 Jan; 19(1):43-8. PubMed ID: 14685755 [TBL] [Abstract][Full Text] [Related]
15. Druggable targets for sudden cardiac death prevention: lessons from the past and strategies for the future. Clements-Jewery H; Andrag E; Curtis MJ Curr Opin Pharmacol; 2009 Apr; 9(2):146-53. PubMed ID: 19167272 [TBL] [Abstract][Full Text] [Related]
16. Model systems for the discovery and development of antiarrhythmic drugs. Nattel S; Duker G; Carlsson L Prog Biophys Mol Biol; 2008; 98(2-3):328-39. PubMed ID: 19038282 [TBL] [Abstract][Full Text] [Related]
18. Atrial-specific drugs: the way to treat atrial fibrillation? Vos MA J Cardiovasc Electrophysiol; 2004 Dec; 15(12):1451-2. PubMed ID: 15610295 [No Abstract] [Full Text] [Related]
19. Non-ion channel blockers as anti-arrhythmic drugs (reversal of structural remodeling). Goette A; Bukowska A; Lendeckel U Curr Opin Pharmacol; 2007 Apr; 7(2):219-24. PubMed ID: 17276728 [TBL] [Abstract][Full Text] [Related]